Cargando…

Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy

Continuous inhibition of angiogenesis beyond progression is an emerging treatment concept in the management of metastatic colorectal cancer patients with prior bevacizumab exposure. Treatment options include the continuation or reintroduction of bevacizumab during the second-line chemotherapy or swi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanat, Ozkan, Ertas, Hulya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390122/
https://www.ncbi.nlm.nih.gov/pubmed/30815371
http://dx.doi.org/10.5306/wjco.v10.i2.52
_version_ 1783398078294786048
author Kanat, Ozkan
Ertas, Hulya
author_facet Kanat, Ozkan
Ertas, Hulya
author_sort Kanat, Ozkan
collection PubMed
description Continuous inhibition of angiogenesis beyond progression is an emerging treatment concept in the management of metastatic colorectal cancer patients with prior bevacizumab exposure. Treatment options include the continuation or reintroduction of bevacizumab during the second-line chemotherapy or switching to a different antiangiogenic monoclonal antibody such as aflibercept or ramucirumab. In the selection of treatment, patient-based factors such as performance status, age, tumor burden, and tolerance and sensitivity to the first-line bevacizumab-based therapy, as well as treatment-related factors such as toxicity, efficacy, and cost, should be taken into consideration.
format Online
Article
Text
id pubmed-6390122
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-63901222019-02-27 Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy Kanat, Ozkan Ertas, Hulya World J Clin Oncol Minireviews Continuous inhibition of angiogenesis beyond progression is an emerging treatment concept in the management of metastatic colorectal cancer patients with prior bevacizumab exposure. Treatment options include the continuation or reintroduction of bevacizumab during the second-line chemotherapy or switching to a different antiangiogenic monoclonal antibody such as aflibercept or ramucirumab. In the selection of treatment, patient-based factors such as performance status, age, tumor burden, and tolerance and sensitivity to the first-line bevacizumab-based therapy, as well as treatment-related factors such as toxicity, efficacy, and cost, should be taken into consideration. Baishideng Publishing Group Inc 2019-02-24 2019-02-24 /pmc/articles/PMC6390122/ /pubmed/30815371 http://dx.doi.org/10.5306/wjco.v10.i2.52 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Minireviews
Kanat, Ozkan
Ertas, Hulya
Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy
title Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy
title_full Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy
title_fullStr Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy
title_full_unstemmed Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy
title_short Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy
title_sort existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390122/
https://www.ncbi.nlm.nih.gov/pubmed/30815371
http://dx.doi.org/10.5306/wjco.v10.i2.52
work_keys_str_mv AT kanatozkan existingantiangiogenictherapeuticstrategiesforpatientswithmetastaticcolorectalcancerprogressingfollowingfirstlinebevacizumabbasedtherapy
AT ertashulya existingantiangiogenictherapeuticstrategiesforpatientswithmetastaticcolorectalcancerprogressingfollowingfirstlinebevacizumabbasedtherapy